Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS
NCT04158674 · Centre Hospitalier Universitaire Dijon · PHASE3 · terminated · last registry update 2026-09-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “There was insufficient funding to continue the study in good conditions.” | – | Registry record, Centre Hospitalier Universitaire Dijon |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE3A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Also stopped (terminated): Philips Clinical & Medical Affairs Global, a drug against PDE3A (NCT04696354)
- 2026-10-15Phase 3 first posted: Merck Sharp & Dohme LLC, Ensifentrine + Standard of Care (SOC) (NCT07874815)
- 2026-04-22Results posted on the registry: Tenax Therapeutics, Inc., Levosimendan (NCT03624010)
- 2026-03-30Phase 3 first posted: Beni-Suef University, pentoxifylline 400 mg (NCT07499817)
- 2026-02-27Phase 3 first posted: Tenax Therapeutics, Inc., TNX-103 (NCT07436689)
- 2025-12-17Phase 3 first posted: Tenax Therapeutics, Inc., TNX-103 + Placebo (NCT07288398)
- 2025-12-04Phase 3 first posted: Chittagong Medical College, Levosimendan (NCT07262723)
- 2025-11-06Results posted on the registry: NICHD Neonatal Research Network, Milrinone + Placebo (5% Dextrose) (NCT02951130)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision